Medtronic has started an investigational device exemption (IDE) study to assess its Abre venous self-expanding stent system in patients suffering from deep venous disease.

Abre is an investigational device being developed for permanent implant in the iliofemoral vein. The device includes a nitinol stent with a tri-axial shaft design, and uses optimised strength and flexibility to exert an outward force for opening the obstructed vein.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

To ensure flexibility and conformability, the stent features an open-cell design with three connection points between the cells.

The multi-centre, single-arm ABRE IDE Study will investigate the safety and effectiveness of the stent in 200 patients with iliofemoral venous outflow obstruction at up to 35 clinical sites in the US and Europe.

ABRE IDE Study European principal investigator Stephen Black said: “Deep venous disease can cause pain, swelling, and blood clots, which can potentially be devastating to patients.

“As a result, there is a critical need for treatment options that are safe, effective, and durable.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData
“We look forward to using the Abre stent in the restoration of patency in patients with deep venous disease.”

“We look forward to using the Abre stent in the restoration of patency in patients with deep venous disease.”

The primary efficacy endpoint of the study is patency at 12 months defined as freedom from occlusion and clinically driven target lesion revascularisation (CD-TLR).

The study will also monitor the incidence of composite major adverse events (MAE) at 30 days after stenting an obstruction in the iliofemoral vein as the primary safety endpoint.

Medtronic expects that the findings from this study will support its US pre-market approval (PMA) application of the Abre stent to treat symptomatic iliofemoral venous outflow obstruction in venous occlusive disease.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact